Skip to main content
Clinical Trials/NCT03918330
NCT03918330CompletedNot Applicable

Spatial Analysis of the Intestinal Microbiota in Healthy Subjects

Örebro University, Sweden1 site in 1 country10 target enrollmentStarted: August 1, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
10
Locations
1
Primary Endpoint
Differences in the composition of the microbiota in luminal and mucosal samples along the large intestine Composition of the microbiota in luminal as well as mucosal samples

Study Overview

Brief Summary

Research on the human intestinal microbiota is common as there is rising evidence of its influence on host physiology and several diseases. Predominantly, it has been based on analyses of faecal samples because of their easy sampling. A minority of studies investigated the gut microbiota using mucosal samples. Not much is known about the spatial differences in microbiota composition along the large bowel. The spatial differences of the gut microbiota without preparation of the bowel have not been analysed yet. Furthermore, the composition of the microbiota of the luminal gut content has not been analysed yet.

This study aims to gain knowledge of the microbial composition of luminal and mucosal samples at different segments of the lower gastrointestinal tract: ileum, caecum, ascending colon, transverse colon, descending colon, sigmoid colon and rectum, as well as of rectal swabs and faecal samples.

Detailed Description

The investigators aim to evaluate complete colonoscopies from 10 healthy subjects. This study is used as a first explorative study of how the human gut microbiota is distributed along the lower gastrointestinal tract. No comparable studies in an uncleansed bowel have been performed so far. The number of subjects is based on other studies investigating the microbial composition of mucosal- and faecal-associated microbiota in which a sample size of 10 was enough to detect a difference. An equal number of men and women will be recruited. Drop-outs will be replaced.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Signed informed consent
  • Age: 18-65 years

Exclusion Criteria

  • Known organic gastrointestinal disease (e.g. inflammatory bowel disease, irritable bowel syndrome, chronic diarrhoea or constipation)
  • History of or present gastrointestinal malignancy or polyposis
  • Recent (gastrointestinal) infection (within last 6 months)
  • History of major gastrointestinal surgery (e.g. gastric bypass)
  • Eosinophilic disorders of the gastrointestinal tract
  • Current communicable disease (e.g. upper respiratory tract infection)
  • Malignant disease and/or patients who are receiving systemic anti-neoplastic agents
  • Psychiatric diseases (e.g. dementia, depression, schizophrenia, autism, Asperger Syndrome) or other incapacity for adequate cooperation
  • Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis)
  • Autoimmune disease and/or patients receiving immunosuppressive medications
  • Major relevant allergies (e.g. food allergy, multiple allergies)
  • Chronic pain syndromes (e.g. fibromyalgia)
  • Chronic fatigue syndrome
  • Obesity (body mass index>30) or metabolic syndrome
  • Antimicrobial treatment or prophylaxis within the last 3 months
  • Other chronic use of drugs that may affect the microbiome, e.g. proton pump inhibitors
  • Females who are pregnant or breast-feeding
  • Known clinically significant abnormal laboratory values
  • Abuse of alcohol or drugs
  • Probiotic intake within the last 6 weeks
  • Bowel cleansing within the last 6 months
  • Any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial

Outcomes

Primary Outcomes

Differences in the composition of the microbiota in luminal and mucosal samples along the large intestine Composition of the microbiota in luminal as well as mucosal samples

Time Frame: 1 day

16S rRNA-based next generation sequencing

Secondary Outcomes

  • Microbial composition of rectal and faecal microbiota(1 day)
  • Metabolic profile in faecal samples along the intestinal tract(1 day)
  • Gene expression of transporters for bacterial products in mucosal biopsies along the colon(1 day)

Investigators

Sponsor
Örebro University, Sweden
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials